CD19 and diffuse large B-cell lymphoma: A multicenter phase 1/2 study ZUMA-1 also showed somwhat better response rates (82%) of another CD19-targeted CAR-T axicabtagene ciloleucel (also known as axi-cel) for refractory DLBCL [7].